Toll-like receptors are a family of proteins that act as the immune system’s early-warning sensors, detecting microbial invaders and damaged cells to trigger a rapid defensive response. Found on and inside immune cells, they recognize conserved molecular signatures from bacteria, viruses, fungi, and parasites, then launch inflammatory and antimicrobial programs before the slower, more targeted arm of immunity kicks in. Humans have ten functional members of this receptor family, each tuned to a different class of threat, and their discovery in the late 1990s fundamentally reshaped how immunologists think about the body’s first line of defense.
From Fruit Flies to a Nobel Prize
The story starts with an unlikely organism. In 1996, Jules Hoffmann’s lab showed that a gene called toll, previously known for its role in fruit fly development, was actually essential for mounting antimicrobial responses in those flies. Two years later, Bruce Beutler identified a mammalian counterpart, TLR4, as the receptor that detects lipopolysaccharide (LPS), a major component of certain bacterial cell walls.1PubMed Central. Of Flies and Men-The Discovery of TLRs Both researchers shared the 2011 Nobel Prize in Physiology or Medicine for this work. Before their discoveries, the innate immune system was considered a blunt, primitive alarm. The realization that it uses sophisticated receptors to distinguish among different types of pathogens rewrote immunology textbooks.
Where They Sit and What They Detect
Human TLRs split into two groups based on where they live in a cell. Cell-surface TLRs, including TLR1, TLR2, TLR4, and TLR5, sit on the outer membrane and sense lipid and protein components of bacteria and other microbes. Endosomal TLRs, including TLR3, TLR7, TLR8, and TLR9, reside inside the cell on internal membrane compartments called endosomes, where they specialize in detecting nucleic acids from pathogens that have been engulfed and broken down.2Cell Press (Immunity). Toll-like receptors: Evolution, signaling, and roles in disease This split is not arbitrary. Keeping the nucleic acid sensors locked away inside the cell helps prevent them from accidentally reacting to the body’s own DNA and RNA floating around in the bloodstream.
Each receptor has a preferred target. TLR4, for instance, recognizes LPS from certain bacteria. TLR5 detects flagellin, the protein that makes up bacterial flagella. TLR2 pairs with either TLR1 or TLR6 to recognize lipoproteins from a range of microbes. On the endosomal side, TLR3 senses double-stranded RNA (a hallmark of viral replication), TLR7 and TLR8 respond to single-stranded RNA, and TLR9 detects DNA sequences rich in unmethylated CpG motifs, which are common in bacterial and viral genomes but rare in mammalian DNA.
The Physical Shape of a Sensor
The external portion of each TLR that faces the outside world or the interior of an endosome is built from repeating structural units called leucine-rich repeats. Stacked together, these repeats form a curved, horseshoe-shaped structure. The concave inner face of this horseshoe is where pathogen-derived molecules typically dock.3Structure. Structural Insights into Toll-like Receptor Recognition of Pathogens and Dangers When the right molecule binds, two TLR horseshoes come together as a pair, and this pairing is what flips the switch to start signaling. The process is not as simple as a key fitting a lock, though. In the case of TLR9, for example, the receptor already exists as a pair in its resting state, and it takes the right DNA ligand to physically rearrange the pair’s internal shape so that the signaling ends inside the cell are brought close enough together to recruit downstream molecules.4Nature Immunology. Ligand-induced conformational changes allosterically activate Toll-like receptor 9 A similar rearrangement happens with TLR8, where binding of an activating molecule reorganizes an existing dimer so that its two cytoplasmic tails converge.5PubMed. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands
How LPS Gets to TLR4
TLR4’s detection of bacterial LPS deserves a closer look because it illustrates how elaborate pathogen sensing can be. LPS does not simply float up and stick to TLR4. A transfer protein called LBP (LPS-binding protein) first latches onto clumps of LPS in the bloodstream. LBP then hands off individual LPS molecules to a shuttle protein called CD14, which in turn delivers them to the TLR4-MD2 complex on the cell surface.6Immunity. Molecular Mechanism of LPS Transfer from LBP to CD14 to TLR4-MD2 This relay system ensures that even tiny amounts of LPS can be captured and concentrated at the receptor, giving the body exquisite sensitivity to bacterial invasion. A single LBP molecule can catalyze multiple rounds of LPS transfer, amplifying the signal.
What Happens After a TLR Fires
Once a TLR is activated, the signaling end inside the cell recruits an adaptor protein called MyD88. This adaptor is shared by almost every TLR and is the linchpin of the pathway: without it, immune cells essentially fail to produce inflammatory cytokines in response to TLR stimulation.7The Journal of Infectious Diseases. Myeloid Differentiation Factor 88—Dependent and —Independent Pathways in Toll-Like Receptor Signaling Through MyD88, signals cascade to activate NF-κB, a master switch that turns on genes for inflammatory cytokines, chemokines, and other molecules that recruit and arm immune cells. MyD88 signaling through TLR2 can also trigger cell-death programs in certain contexts, adding another layer to the response.8PubMed Central. The apoptotic signaling pathway activated by Toll-like receptor-2
Not every TLR relies exclusively on MyD88. TLR3 signals through an alternative adaptor called TRIF, which activates a transcription factor called IRF3 and drives the production of type I interferons, proteins that are especially important for antiviral defense. TLR4 is unique in that it can use both the MyD88 and TRIF pathways, making it the most versatile member of the family.9PubMed Central. Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation
Detecting Viruses Inside the Cell
Viruses present a particular challenge because many of their components resemble the host’s own molecules. The endosomal TLRs solve this problem by only encountering nucleic acids after a microbe has been swallowed up and broken apart inside the cell. Enzymes called DNases and RNases chop up the engulfed material, and the resulting fragments are what TLR7, TLR8, and TLR9 actually recognize. Specifically, DNase II digests DNA into single-stranded fragments that TLR9 can bind, while RNase T2 cleaves RNA into the small pieces that TLR7 and TLR8 respond to.10PubMed Central. Nucleic Acid Sensing by Toll-Like Receptors in the Endosomal Compartment This requirement for enzymatic processing acts as a safety mechanism. The body’s own nucleic acids, circulating freely outside cells, rarely end up processed inside endosomes in the same way, so TLRs usually ignore them.
When TLRs React to the Body’s Own Molecules
The safety mechanisms are not foolproof. Damaged, stressed, or dying cells release molecules called damage-associated molecular patterns (DAMPs) that can activate TLRs just as microbial products do.11PubMed Central. Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy In the context of a wound or a heart attack, this response is useful: it recruits immune cells to clean up debris and begin repair. But when DAMP-driven TLR activation becomes chronic or misdirected, it can fuel disease.
Autoimmunity is a striking example. In lupus, the immune system attacks the body’s own DNA and RNA-containing complexes. Research has shown that TLR7, which senses single-stranded RNA, promotes lupus-like disease in mouse models, while TLR9, which senses DNA, has a more complicated and sometimes protective role, even though it is the receptor that drives anti-DNA autoantibody production.12PubMed Central. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors In mice lacking TLR7, the production of antibodies against RNA-containing targets was blocked, while antibodies against DNA-containing targets were unaffected.13Immunity. Toll-like Receptors 7 and 9 Mitigate Lupus Pathogenesis by Distinct Mechanisms The finding that different TLRs can push an autoimmune disease in opposite directions complicates any blanket strategy of simply blocking TLR signaling to treat autoimmunity.
Sepsis represents another case where TLR activation becomes dangerous. When a severe infection triggers an overwhelming, body-wide inflammatory response, TLRs are major contributors to the resulting cytokine storm, a flood of inflammatory molecules that can damage organs and become life-threatening.14PubMed Central. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets
The Dual Role in Cancer
TLRs play a genuinely paradoxical role in tumors. When activated on immune cells, TLRs can stimulate anti-tumor responses by ramping up inflammatory cytokines and promoting tumor cell death. But when activated directly on tumor cells, TLRs can promote cancer cell survival and proliferation. TLR2 activation on immune cells tends to boost anti-tumor immunity, while TLR2 signaling on tumor cells themselves activates pro-survival pathways via NF-κB. TLR4 behaves similarly: its activation on immune cells generates a useful defensive response, but activation on tumor cells can create an immunosuppressive environment that helps the tumor evade destruction.15Medicine in Drug Discovery. The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy Whether TLR activation helps or hurts depends on which cell type is doing the sensing, which TLR is involved, and the specific tumor microenvironment. This complexity makes TLR-targeting cancer drugs a high-wire act: the same receptor can be anti-tumor in one context and pro-tumor in another.
TLR-Based Drugs and Vaccine Adjuvants
Despite the complexity, researchers are actively exploiting TLR biology for therapies. TLR agonists, molecules that deliberately switch on a TLR, are being used and studied as vaccine adjuvants. By triggering an innate immune alarm alongside a vaccine antigen, they push the immune system to mount a stronger and more durable adaptive response.16PubMed Central. Toll-like receptor agonists as cancer vaccine adjuvants Several modern vaccines already include TLR-activating adjuvants. On the antiviral side, TLR agonists and antagonists are being explored for treating chronic infections where the immune response needs a boost or, conversely, where excessive TLR-driven inflammation is causing tissue damage.17PubMed Central. Novel drugs targeting Toll-like receptors for antiviral therapy
The best-known approved TLR drug is imiquimod, a cream used to treat certain skin conditions including superficial skin cancers and genital warts. It works by activating TLR7, which stimulates local immune cells to attack abnormal tissue.18PubMed Central. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes Beyond imiquimod, a range of both small-molecule and macromolecular TLR agents are in preclinical and clinical testing for infectious diseases, cancer, and autoimmune conditions.19Trends in Biotechnology. Macromolecular Toll-like receptor agents and assemblies The challenge is specificity: activating the right TLR, on the right cell, at the right dose, without triggering a systemic inflammatory cascade.
How the Body Keeps TLR Signaling in Check
Given how potent TLR activation can be, the body has evolved multiple brake systems to prevent the response from spiraling out of control.20PubMed. Negative regulation of toll-like receptor-mediated immune responses These operate at nearly every level of the signaling chain. One well-studied example is Tollip, an intracellular protein that physically associates with TLR2 and TLR4 and suppresses the activity of a key enzyme in the signaling cascade. By dampening this enzyme, Tollip limits the production of inflammatory mediators during infection and prevents the immune response from overshooting.21PubMed. Negative regulation of toll-like receptor-mediated signaling by Tollip
Beyond dedicated inhibitor proteins, TLR activity is regulated through post-translational modifications: chemical tags like phosphate groups, ubiquitin chains, and methyl or acetyl groups that are added to TLRs and their downstream partners to speed up, slow down, or redirect signaling.22Immunity. Post-translational modifications in innate immunity and inflammatory responses Cells also control where TLRs travel inside the cell, how quickly they are recycled or degraded, and whether co-receptors needed for ligand binding are available.23PubMed Central. Molecular mechanisms of regulation of Toll-like receptor signaling When any of these regulatory layers malfunction, the result can be chronic inflammation, autoimmune disease, or impaired defense against infection.
TLR Signaling and the Inflammasome
TLRs do not work in isolation. One of their most important partnerships is with the inflammasome, a multi-protein complex inside the cell that processes and releases mature forms of the inflammatory cytokines IL-1β and IL-18. TLR activation provides the first signal by turning on the genes that encode the inactive precursors of these cytokines. A second signal, often from a different sensor family called NLRs, then triggers the inflammasome to assemble and convert those precursors into their active forms.24PubMed Central. Toll-like receptor (TLR) and inflammasome actions in the central nervous system This two-step system is another safeguard: it takes converging signals from different pathways to fully unleash these powerful inflammatory molecules.25PubMed. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs This cooperation between TLRs and the inflammasome is especially relevant in the brain, where overactivation of both pathways has been linked to neurodegenerative diseases.
TLRs and the Metabolism of Immune Cells
When a TLR fires, it does not just switch on genes for inflammatory proteins. It also reprograms the cell’s internal metabolism. Immune cells that have been activated through TLR4, for example, shift heavily toward a fast-burning metabolic mode that favors rapid energy production and the building blocks needed for inflammatory mediators. For a long time, researchers assumed this metabolic shift was a universal feature of TLR activation. More recent work has shown that the picture is considerably more nuanced: different microbial stimuli, acting through different TLRs, produce distinct metabolic profiles rather than a single standard rewiring.26PubMed. Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses This means that the metabolic consequences of TLR signaling depend on which receptor is involved and what tissue the cell is sitting in, making “immunometabolism” one of the more active and fast-moving corners of TLR research.
TLRs in the Gut and the Commensal Balancing Act
Perhaps nowhere is the dual nature of TLRs more apparent than in the intestine. The gut is home to trillions of commensal bacteria, many of which carry the same molecular patterns that TLRs are designed to detect. Rather than constantly triggering inflammation, TLR signaling in the gut helps maintain the integrity of the intestinal barrier. TLR2, for instance, promotes the assembly of tight junctions, the protein seals that hold intestinal lining cells together, and supports cell survival through a pro-survival signaling pathway. In mice lacking TLR2, intestinal stress led to early breakdown of these junctions and worse inflammation. Treating mice with a TLR2-activating compound actually suppressed colitis and restored barrier integrity.27PubMed. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function So in the gut, a TLR that might elsewhere trigger inflammation instead plays a protective, housekeeping role, underscoring that context is everything with this receptor family.
An Ancient Evolutionary Heritage
TLRs are not a mammalian invention. Phylogenetic analyses spanning hundreds of vertebrate species have identified eight major TLR subfamilies, with TLR3 likely representing the most ancient lineage, emerging before the evolutionary branching point that separated vertebrates from other deuterostomes.28PubMed Central. Evolutionary History of the Toll-Like Receptor Gene Family across Vertebrates Even beyond vertebrates, TLR-like proteins are found in cnidarians (jellyfish, corals) and across the protostome lineage (insects, worms, mollusks), indicating that the basic TLR architecture predates the split between these major animal groups over half a billion years ago.29PubMed Central. The evolution of the metazoan Toll receptor family and its expression during protostome development
The evolutionary forces shaping TLRs are telling. Across vertebrate TLRs, the dominant evolutionary pressure has been purifying selection, meaning mutations that break the receptor’s function tend to be eliminated. But the portions of TLRs that directly contact pathogen molecules show clear signatures of positive selection, the hallmark of an evolutionary arms race between host sensors and microbial evasion strategies. Interestingly, TLRs that sense non-viral pathogens show stronger positive selection than the viral-sensing TLRs, suggesting that the nucleic-acid-detecting receptors are more indispensable and less free to vary.30PubMed Central. Evolutionary History of the Toll-Like Receptor Gene Family across Vertebrates Different animal lineages have expanded or contracted their TLR repertoires independently, so a sea urchin may have hundreds of TLR genes while an insect gets by with far fewer. The human set of ten is a relatively streamlined toolkit, refined over hundreds of millions of years of host-pathogen conflict.
TLRs and Implanted Medical Devices
A surprising frontier in TLR research involves medical implants. When a synthetic material like a hydrogel is placed in the body, proteins from blood plasma adsorb onto its surface and can become structurally altered in ways that make them resemble DAMPs. These surface-adsorbed proteins then activate TLR4, and in living tissue, both TLR2 and TLR4 contribute to the inflammatory response and fibrous capsule that the body builds around the implant.31PubMed Central. Damage Associated Molecular Patterns (DAMPs) Mediate the Foreign Body Response to Poly(ethylene glycol) Diacrylate Hydrogels via Toll like Receptors Understanding this link between TLRs and the foreign body response could lead to better biomaterial designs that minimize chronic inflammation around implants, pacemaker leads, or drug-delivery devices. It also reinforces that TLRs are not just about fighting infections; they are general-purpose sensors of anything the body interprets as abnormal or threatening.